In a recently available problem of the by demonstrating that like
In a recently available problem of the by demonstrating that like imatinib [2], nilotinib can inhibit LCK, a Src-family kinase that takes on a critical part in TCR activation [3]. Inhibition of LCK by nilotinib and imatinib was analysed by analyzing the effects of every medication on LCK phosphorylation of the substrate peptide. Dynamic LCK … [Read more…]